ACSL4 and laryngotracheoesophageal cleft: Collectively, RBM15 promotes KDM5B expression to inhibit ferroptosis and regulate the FER1L4/GPX4 and KCNQ1OT1/ACSL4 signaling axes, thereby enhancing cisplatin resistance in LC and representing a potential therapeutic target.